Hana Chen-Walden
Nessuna posizione attualmente
Profilo
Hana Chen-Walden worked as the Director-International Regulatory Affairs at Covalent Group, Inc. from 2000 to 2003.
She then served as the Chief Medical Director at Boston Therapeutics, Inc. and as an Independent Director at BioXyTran, Inc. Dr. Chen-Walden holds a doctorate degree from Tel-Aviv University.
Precedenti posizioni note di Hana Chen-Walden
| Società | Posizione | Fine |
|---|---|---|
| BIOXYTRAN, INC. | Direttore/Membro del Consiglio | 19/04/2024 |
| Covalent Group, Inc. | Consigliere Generale | 01/01/2003 |
| NANOMIX CORPORATION | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Hana Chen-Walden
| Tel-Aviv University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOXYTRAN, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Covalent Group, Inc. | Commercial Services |
- Borsa valori
- Insiders
- Hana Chen-Walden
